| Description | Disopyramide, a sodium channel blocker in the Class of 1a anti-arrhythmic agent, is used in the treatment of Ventricular Tachycardia. Disopyramide has a negative inotropic effect on the ventricular myocardium, resulting in a significant decrease in contractility. |
| Synonyms | SC13957, SC 13957, SC-13957 |
| molecular weight | 437.47 |
| Molecular formula | C21H32N3O5P |
| CAS | 22059-60-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | H2O: Insoluble DMSO: Soluble |
| References | 1. Anzawa R, Ishikawa S, Tanaka Y, Okazaki F, Mochizuki S. Increased AAI mode pacing threshold after termination of atrial fibrillation by acute administration of disopyramide phosphate. Europace. 2006 May;8(5):345-8. PubMed PMID: 16635993. 2. Anzawa R, Ishikawa S, Tanaka Y, Okazaki F, Mochizuki S. Atrial pacing failure following termination of atrial fibrillation by acute administration of disopyramide phosphate. J Interv Card Electrophysiol. 2005 Jun;13(1):51-3. PubMed PMID: 15976979. 3. Tsuchioka Y, Nakagawa H, Yamagata T, Sakura E, Hashimoto M, Okamoto M, Matsuura H, Kajiyama G. [Effects of verapamil and disopyramide phosphate on the termination, reinduction and long-term prevention of paroxysmal supraventricular tachycardia]. Kokyu To Junkan. 1990 Mar;38(3):243-8. Japanese. PubMed PMID: 2109870. 4. Means JR, Hjelle JJ, Kotsonis FN. The effects of disopyramide phosphate on serum glucose and glucose counterregulation in the dog. Fundam Appl Toxicol. 1985 Jun;5(3):539-45. PubMed PMID: 3891480. |